Navigate our catalog by research domain. Each category groups compounds by their primary mechanism of action and research application area, reflecting the scientific literature and standard laboratory classification conventions.
Glucagon-like peptide-1 (GLP-1) receptor agonists represent one of the most actively studied areas in contemporary metabolic research. This category includes GLP-1 mono-agonists, dual GIP/GLP-1 agonists, and triple incretin/glucagon agonists, each occupying a distinct mechanistic position in the literature. All compounds are available for same-day shipping from our Houston, TX facility. View individual compound profiles including Retatrutide, Tirzepatide, and BPC-157. Browse by research area: GLP-1 Research, Tissue Repair, Longevity Peptides, Cognitive Research, and Dermatology Research.
Research applications include GLP-1 receptor pharmacology, incretin biology, insulin secretion pathway studies, glucagon counter-regulation, and adipose tissue metabolism. These compounds are supplied as lyophilized research-grade materials for qualified laboratory use.
Semaglutide provides a well-characterized single-receptor tool. Tirzepatide enables dual-axis research. Retatrutide, as a triple agonist, is of particular interest for studying combined incretin and glucagon pathway interactions in cellular and animal models.
This category encompasses synthetic peptides under active research investigation for their roles in cellular signaling pathways related to tissue homeostasis, repair mechanisms, and angiogenesis. Both BPC-157 and TB-500 have substantial bodies of peer-reviewed literature in rodent and in vitro models.
BPC-157 (Body Protection Compound 157) is a pentadecapeptide studied for its cytoprotective effects and interactions with the nitric oxide system. TB-500 is a synthetic fragment of Thymosin Beta-4, studied for its role in actin sequestration and cell migration. Together in the Wolverine Blend, researchers can study potential synergistic signaling activity.
All compounds in this category are available in lyophilized form with full HPLC and MS verification documentation.
Growth hormone secretagogues (GHS) and growth hormone-releasing hormone (GHRH) analogs represent a well-established class of research compounds used to study the hypothalamic-pituitary-somatotroph axis. This category includes both GHRH analogs and ghrelin-mimetic GH secretagogues.
CJC-1295 is a DAC-modified GHRH analog with extended half-life, used in studies of sustained GH axis stimulation. Ipamorelin is a selective GHS receptor agonist notable for its clean pharmacological profile, stimulating GH release without significant co-secretion of cortisol or prolactin at research concentrations. Tesamorelin is a stabilized GHRH analog with a distinctive N-terminal modification.
These compounds are frequently used in combination studies to examine synergistic GH axis activity. The CJC-1295/Ipamorelin blend is pre-formulated for researchers studying combined GHRH + GHS effects.
Longevity research encompasses a broad range of biological domains, telomere biology, gene expression regulation, cellular senescence, oxidative stress response, and pineal function. The compounds in this category are studied across these domains in cellular and animal model contexts.
Epithalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide originally derived from pineal gland extract research. Published studies from Russian gerontology institutions document its effects on telomerase activity in cell cultures, melatonin production in pineal cells, and lifespan parameters in multiple animal models. It remains an active area of investigation in cellular aging research.
GHK-Cu (Glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide with a documented ability to modulate gene expression in vitro. Research has identified over 4,000 genes affected by GHK-Cu treatment in human cell cultures, spanning antioxidant defense, collagen synthesis, and anti-inflammatory pathways.
The melanocortin system encompasses five G protein-coupled receptors (MC1R–MC5R) that mediate a wide range of physiological functions including pigmentation, energy homeostasis, immune modulation, and autonomic nervous system regulation. Melanocortin receptor pharmacology is a defined area of research interest with active literature.
PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist with selectivity for MC3R and MC4R. It is used as a pharmacological tool compound in receptor binding studies, central nervous system pathway mapping, and comparative melanocortin pharmacology. Its cyclic structure provides conformational stability that makes it particularly useful for receptor binding assays.
Supplied in lyophilized form, COA verified, with full mass spectrometry identity confirmation.
Research blends combine two or more compounds into a single lyophilized preparation, enabling researchers to study combined pathway activity without the logistics of separate reconstitution and dosing. Each blend is formulated at defined ratios and verified as a complete preparation, not a mixture of separate powders.
The Wolverine Blend combines BPC-157 and TB-500 in a standardized ratio for researchers studying potential synergistic interactions between cytoprotective and actin-dynamics signaling pathways. The CJC-1295/Ipamorelin blend combines GHRH analog and GHS receptor agonist activity for researchers studying combined growth hormone axis stimulation.
All blends are subject to the same ≥99% purity verification and COA documentation requirements as single-compound products. Batch-specific documentation is provided with every order.
⚠ FOR RESEARCH USE ONLY, All compounds and blends listed are supplied exclusively for in vitro and laboratory research applications. Not for human consumption, veterinary use, or clinical application. Category descriptions reflect scientific literature and research classifications, they do not constitute therapeutic claims or medical guidance. Researchers are responsible for all applicable institutional and regulatory compliance requirements.